Pear Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

peartherapeutics.com

Founded Year

2013

Stage

Corporate Minority - P2P | Alive

Total Raised

$334.94M

About Pear Therapeutics

Pear Therapeutics discovers, develops, and delivers clinically-validated Prescription Digital Therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effection solutions for payers.

Pear Therapeutics Headquarter Location

200 State St

Boston, Massachusetts, 02109,

United States

646-932-2774

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Pear Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pear Therapeutics is included in 8 Expert Collections, including Digital Health.

D

Digital Health

13,204 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)

M

Mental Health Tech

1,170 items

This collection includes companies applying technology to problems of emotional, psychological, and social well-being. Examples include companies working in areas such as substance abuse, eating disorders, stress reduction, depression, PTSD, and anxiety.

D

Digital Health 150

300 items

2019's cohort of the most promising digital health startups transforming the healthcare industry

S

Sleep Health & Wellness

800 items

These companies aim to assess or improve the quantity/quality of sleep, or use sleep data in the monitoring or diagnosis of other health conditions.

M

Medical Devices

11,637 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Pear Therapeutics Patents

Pear Therapeutics has filed 13 patents.

The 3 most popular patent topics include:

  • Psychiatric diagnosis
  • Graphical user interface elements
  • Cognitive behavioral therapy
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/5/2018

4/27/2021

Graphical user interface elements, Graphical control elements, Graphical user interfaces, Graphical user interface testing, Live-preview digital cameras

Grant

Application Date

10/5/2018

Grant Date

4/27/2021

Title

Related Topics

Graphical user interface elements, Graphical control elements, Graphical user interfaces, Graphical user interface testing, Live-preview digital cameras

Status

Grant

Latest Pear Therapeutics News

Pear Therapeutics Announces the Inclusion of QuickMD in Its Telehealth Provider Experience Initiative

May 12, 2022

Pear’s second telehealth offering for reSET-O® is with QuickMD, a telemedicine platform providing consultations and urgent care Pear is working with QuickMD to assist eligible patients in their recovery from opioid use disorder May 12, 2022 08:00 AM Eastern Daylight Time BOSTON--( BUSINESS WIRE )-- Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the expansion of its program to offer patients seeking treatment for addiction access to a telehealth provider through its “ find a provider tool ”, along with in-person care options. Pear’s second telehealth offering in this program will offer eligible patients with opioid use disorder (OUD), who prefer a telemedicine solution, access to reSET-O through QuickMD , a telemedicine platform providing consultations and urgent care over phone and video. According to new data released by the U.S. Centers for Disease Control and Prevention, America’s addiction crisis is the deadliest it has ever been with overdose deaths reaching an all-time high in 2021.1,2 Throughout the Covid-19 pandemic, telemedicine and PDTs have helped in providing patients with 24/7 access and care. The number of people who used telemedicine doubled from 39.4% to 79.5% in 2020.3 Innovative treatment options like reSET-O can help to address the ongoing opioid epidemic by reaching patients where they are and to reduce the stigma often associated with opioid addiction. “We are proud to be able to offer compassionate care to patients suffering from OUD through our team of dedicated doctors and with recovery tools such as reSET-O that complement medication-assisted treatment,” said Jared Sheehan, Chief Operating Officer at QuickMD. “QuickMD works to offer treatment options to our patients that provide security and privacy in a telemedicine environment, all from the privacy of a patient’s home.” “Pear is pleased to work with telehealth providers in providing innovative, FDA-authorized treatments that enable round-the-clock access to assist eligible patients in their recovery journey during these difficult times,” said Julia Strandberg, Chief Commercial Officer at Pear Therapeutics. “After so many uncertain months, it is important to meet people where they are and where they feel comfortable, providing them with access to the care they need.” Pear’s reSET-O, for the treatment of OUD, has been measured in real-world use and its therapeutic content studied in randomized controlled trials, with results published in peer-reviewed medical journals4,5. reSET-O, which is adjunctive to outpatient counselling, provides patients with cognitive behavioral therapy, fluency training, and contingency management, while clinicians receive access to clinical dashboards to inform in-office and tele visits. About Pear Therapeutics Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com . reSET-O Important Safety Information Indications for Use reSET-O is intended to increase retention of patients with Opioid Use Disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only prescription digital therapeutic. Important Safety Information: Warnings: reSET-O is intended for patients whose primary language is English with a reading level of 7th grade or above, and who have access to an Android/iOS tablet or smartphone. reSET-O is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications). Clinicians should not use reSET-O to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET-O to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room. reSET-O is not intended to be used as a stand-alone therapy for Opioid Use Disorder (OUD). reSET-O does not replace care by a licensed medical practitioner and is not intended to reduce the frequency or duration of in-person therapy. reSET-O does not represent a substitution for a patient’s medication. Patients should continue to take their medications as directed by their healthcare provider. Patients with opioid use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population. Patients with opioid use disorder have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion. Clinicians should undertake standard of care to monitor patients for medical problems and mental health disease, including risk for harming others and/or themselves. The long-term benefit of reSET-O has not been evaluated in studies lasting beyond 12 weeks (84 days) in the OUD population. The ability of reSET-O to prevent potential relapse after therapy discontinuation has not been studied. This Press Release does not include all the information needed to use reSET-O safely and effectively. Please see the Clinician Brief Summary Instructions for reSET-O for more information. Forward-Looking Statements from Pear Therapeutics Certain statements and projections in this press release may be considered forward-looking statements within the meaning of the federal securities laws. Forward looking statements generally relate to future events or involving, or future performance of, Pear. For example, statements regarding round-the-clock access to, and the continued availability of, the QuickMD telehealth platform are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “aim”, “estimate”, “anticipate”, “believe”, or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Pear and its management are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) delay or reluctance by patients and/or providers to adopt, request or use Pear’s products, (ii) whether Pear’s initiative in telehealth with QuickMD or other telehealth providers will be successful, (iii) changes in applicable laws or regulations; and (iv) other risks and uncertainties set forth in Pear’s future filings with the SEC. These filings will identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and Pear assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Pear gives no assurance that Pear will achieve its expectations. The inclusion of any statement in this communication does not constitute an admission by Pear or any other person that the events or circumstances described in such statement are material. References: Campbell ANC, Nunes EV, Matthews AG, et al. Internet-delivered treatment for substance abuse: a multisite randomized controlled trial. Am J Psychiatry. 2014;171(6):683-690. Christensen DR, Landes RD, Jackson L, et al. Adding an Internet-delivered treatment to an efficacious treatment package for opioid dependence. J Consult Clin Psychol. 2014;82(6):964-972. doi:10.1037/a0037496.

Pear Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Pear Therapeutics Rank

You May Also Like

Click Therapeutics Logo
Click Therapeutics

Click Therapeutics develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click's Digital Therapeutics enable change within individuals and are designed to be used independently or in conjunction with biomedical treatments. Click's smoking cessation program is currently available nationwide through a variety of payers, providers, and employers. Click Therapeutics was founded in 2012 and is based in New York, New York.

Happify Logo
Happify

Happify is a LifeTech company that delivers digital therapeutics and care delivery models to improve mental and physical health. Happify Health’s safe, effective digital tools use scientific research from positive psychology, CBT, and mindfulness, combined with a gamified approach and technology, to impact everyday lives. Happify Health's clinically-validated platform provides global access to a comprehensive, evidence-based intervention catalog.

Workit Health Logo
Workit Health

Workit provides a 90-day digital program that pairs one-on-one support from professionally-certified counselors with interactive, customized digital content. The core of the program is based on evidence-based therapies for addiction, including Motivational Interviewing (MI), Relapse Prevention Therapy, (RPT), Cognitive Behavioral Therapy (CBT), and Brief Interventions (BI).

Big Health Logo
Big Health

Big Health offers digital therapeutics servies including fully automated behavioral programs. The company offers Sleepio for users in need of help with sleep issues.

BrightInsight Logo
BrightInsight

BrightInsight provides a global platform for biopharma and MedTech regulated digital health solutions. The company helps accelerate time to market for apps, algorithms, medical devices, connected combination products, diagnostics, and Software as a Medical Device (SaMD). BrightInsight offers configurable software modules and a proven platform built under a Quality Management System to support global security, privacy, and regulatory requirements. When building digital health products on the BrightInsight Platform, compliance is future-proofed as intended use changes scale across geographies.

H
HealthPrize Technologies

HealthPrize provides a Software-as-a-Service (SaaS), HIPAA-compliant platform and services to create unique digital experiences proven to drive patient engagement, education and increased medication adherence for healthcare companies and pharmaceutical brands. Using a proprietary gamification approach, and patented technology, combined with a deep understanding of behavioral sciences and patient psychology, HealthPrize consistently delivers high levels of patient engagement resulting in over 50% increased lifts in Rx adherence versus control.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.